SCHEMBL26205886

SCHEMBL26205886

Cc1c(F)cc(NC2=CC(=O)N(c3ccc(O)cc3)C2=O)cc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.50
▸ MEN1 O00255 4/20 0.50
▸ ALDH1A1 P00352 4/20 0.37
▸ KDM4E B2RXH2 3/20 0.37
▸ HSP90AA1 P07900 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ MGLL Q99685 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ ESR1 P03372 4/20 0.36
▸ ESR2 Q92731 3/20 0.36
▸ DNM1 Q05193 1/20 0.36
▸ POLB P06746 2/20 0.35
▸ APAF1 O14727 1/20 0.35
▸ MAPT P10636 3/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ ADRB2 P07550 1/20 0.34
▸ PLEC Q15149 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26205834 0.91 KMT2A (0.54) KMT2AMEN1ALDH1A1KDM4EMGLL
SCHEMBL26205855 0.90 MEN1 (0.52) KMT2AMEN1ALDH1A1KDM4EMGLL
SCHEMBL24430026 0.90 KMT2A (0.52) KMT2AMEN1ALDH1A1KDM4EHSP90AA1
SCHEMBL26205843 0.87 MEN1 (0.68) KMT2AMEN1ALDH1A1KDM4EMGLL
SCHEMBL26205804 0.87 MEN1 (0.49) KMT2AMEN1ALDH1A1KDM4EHSP90AA1
SCHEMBL26205848 0.85 ALDH1A1 (0.54) KMT2AMEN1ALDH1A1KDM4EMAPK1
SCHEMBL26205857 0.85 MEN1 (0.51) KMT2AMEN1ALDH1A1KDM4EMAPK1
SCHEMBL26205901 0.85 KMT2A (0.48) KMT2AMEN1ALDH1A1KDM4EMAPK1
SCHEMBL26205908 0.85 MEN1 (0.48) KMT2AMEN1ALDH1A1KDM4EHSP90AA1
SCHEMBL24430074 0.85 MEN1 (0.50) KMT2AMEN1ALDH1A1KDM4EMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease Southern Reserach Institute (US) 2023-09-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease HMOX1, GLS, HMOX2 KMT2A 2088/4885MEN1 4171/4885ALDH1A1 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback